All In Biotech

Drug Trial Radar · NCT07611162

Comparative Effectiveness of Alginate, Magaldrate, Sucralfate, Proton Pump Inhibitors, and Diet in Laryngopharyngeal Reflux Disease

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

May 1, 2030

Study completion May 1, 2030

Sponsor

Lead sponsor
University of MonsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized controlled trial is to compare the effectiveness of different treatments for laryngopharyngeal reflux disease (LPRD) in adult patients with confirmed symptoms and signs of the condition. The main question it aims to answer is: Which treatment (Proton Pump Inhibitors (PPIs), alginate, magaldrate, sucralfate, or diet) leads to the greatest improvement in LPRD symptoms and clinical signs over 3 months? Researchers will compare proton pump inhibitors to alternative medical treatments and dietary management to see which approach is most effective and better tolerated. Participants will: * undergo a clinical ENT examination with scoring of reflux signs (RSA) * complete symptom questionnaires (RSS) assessing severity, frequency, and impact of symptoms * receive one of the study treatments (medication or dietary intervention) * be evaluated at baseline and again after 3 months of treatment

Conditions

  • Laryngopharyngeal Reflux Disease

Interventions

  • AlginateDrug

    Use of Gaviscon anti-acid, anti-reflux

  • MagaldrateDrug

    use of Riopan drug

  • SucralfateDrug

    use of Kéal sucralfate

  • Proton Pump Inhibitor (PPI) TherapyDrug

    Use of Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole

  • DietBehavioral

    Patients are recommended to adhere to a 3-month low-fat, low quick-release sugar, high-protein, alkaline, and plant-based diet. The consumption of fish and meat was authorized but reduced to low-fat fish and meat. The anti-reflux diet considered the exclusion/reduction of additional triggers such as caffeine or theine, spices, tomatoes, fatty, cheese alcohol, and sparkling beverages.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of the effectiveness of each intervention based on changes in Reflux Symptom Score (RSS) and Reflux Sign Assessment (RSA) from pre- to post-treatment follow-up.Time frame: From enrollment to the end of treatment at 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Mons

    Mons, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.